Copyright Reports & Markets. All rights reserved.

Global Hodgkin Lymphoma Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Hodgkin Lymphoma Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Hodgkin Lymphoma Treatment Market Size Growth Rate by Product
      • 1.4.2 Alocrest
      • 1.4.3 ANK Program
      • 1.4.4 Azacitidine
      • 1.4.5 BMS-986016
      • 1.4.6 BPX-501
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Hodgkin Lymphoma Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Research Center
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Hodgkin Lymphoma Treatment Market Size
      • 2.1.1 Global Hodgkin Lymphoma Treatment Revenue 2014-2025
      • 2.1.2 Global Hodgkin Lymphoma Treatment Sales 2014-2025
    • 2.2 Hodgkin Lymphoma Treatment Growth Rate by Regions
      • 2.2.1 Global Hodgkin Lymphoma Treatment Sales by Regions
      • 2.2.2 Global Hodgkin Lymphoma Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Hodgkin Lymphoma Treatment Sales by Manufacturers
      • 3.1.1 Hodgkin Lymphoma Treatment Sales by Manufacturers
      • 3.1.2 Hodgkin Lymphoma Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Hodgkin Lymphoma Treatment Revenue by Manufacturers
      • 3.2.1 Hodgkin Lymphoma Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Hodgkin Lymphoma Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Hodgkin Lymphoma Treatment Price by Manufacturers
    • 3.4 Hodgkin Lymphoma Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Hodgkin Lymphoma Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Hodgkin Lymphoma Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Hodgkin Lymphoma Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Hodgkin Lymphoma Treatment Sales by Product
    • 4.2 Global Hodgkin Lymphoma Treatment Revenue by Product
    • 4.3 Hodgkin Lymphoma Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Hodgkin Lymphoma Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Hodgkin Lymphoma Treatment by Countries
      • 6.1.1 North America Hodgkin Lymphoma Treatment Sales by Countries
      • 6.1.2 North America Hodgkin Lymphoma Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Hodgkin Lymphoma Treatment by Product
    • 6.3 North America Hodgkin Lymphoma Treatment by End User

    7 Europe

    • 7.1 Europe Hodgkin Lymphoma Treatment by Countries
      • 7.1.1 Europe Hodgkin Lymphoma Treatment Sales by Countries
      • 7.1.2 Europe Hodgkin Lymphoma Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Hodgkin Lymphoma Treatment by Product
    • 7.3 Europe Hodgkin Lymphoma Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Hodgkin Lymphoma Treatment by Countries
      • 8.1.1 Asia Pacific Hodgkin Lymphoma Treatment Sales by Countries
      • 8.1.2 Asia Pacific Hodgkin Lymphoma Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Hodgkin Lymphoma Treatment by Product
    • 8.3 Asia Pacific Hodgkin Lymphoma Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Hodgkin Lymphoma Treatment by Countries
      • 9.1.1 Central & South America Hodgkin Lymphoma Treatment Sales by Countries
      • 9.1.2 Central & South America Hodgkin Lymphoma Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Hodgkin Lymphoma Treatment by Product
    • 9.3 Central & South America Hodgkin Lymphoma Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Hodgkin Lymphoma Treatment by Countries
      • 10.1.1 Middle East and Africa Hodgkin Lymphoma Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Hodgkin Lymphoma Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Hodgkin Lymphoma Treatment by Product
    • 10.3 Middle East and Africa Hodgkin Lymphoma Treatment by End User

    11 Company Profiles

    • 11.1 Cell Medica Limited
      • 11.1.1 Cell Medica Limited Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Cell Medica Limited Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Cell Medica Limited Hodgkin Lymphoma Treatment Products Offered
      • 11.1.5 Cell Medica Limited Recent Development
    • 11.2 Cellular Biomedicine Group, Inc.
      • 11.2.1 Cellular Biomedicine Group, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Cellular Biomedicine Group, Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Cellular Biomedicine Group, Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.2.5 Cellular Biomedicine Group, Inc. Recent Development
    • 11.3 Constellation Pharmaceuticals, Inc.
      • 11.3.1 Constellation Pharmaceuticals, Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Constellation Pharmaceuticals, Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Constellation Pharmaceuticals, Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.3.5 Constellation Pharmaceuticals, Inc. Recent Development
    • 11.4 Curis, Inc.
      • 11.4.1 Curis, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Curis, Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Curis, Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.4.5 Curis, Inc. Recent Development
    • 11.5 Faron Pharmaceuticals Oy
      • 11.5.1 Faron Pharmaceuticals Oy Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Faron Pharmaceuticals Oy Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Faron Pharmaceuticals Oy Hodgkin Lymphoma Treatment Products Offered
      • 11.5.5 Faron Pharmaceuticals Oy Recent Development
    • 11.6 Fate Therapeutics, Inc.
      • 11.6.1 Fate Therapeutics, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Fate Therapeutics, Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Fate Therapeutics, Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.6.5 Fate Therapeutics, Inc. Recent Development
    • 11.7 Gamida Cell Ltd.
      • 11.7.1 Gamida Cell Ltd. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Gamida Cell Ltd. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Gamida Cell Ltd. Hodgkin Lymphoma Treatment Products Offered
      • 11.7.5 Gamida Cell Ltd. Recent Development
    • 11.8 Gilead Sciences, Inc.
      • 11.8.1 Gilead Sciences, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Gilead Sciences, Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Gilead Sciences, Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.8.5 Gilead Sciences, Inc. Recent Development
    • 11.9 Incyte Corporation
      • 11.9.1 Incyte Corporation Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Incyte Corporation Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Incyte Corporation Hodgkin Lymphoma Treatment Products Offered
      • 11.9.5 Incyte Corporation Recent Development
    • 11.10 Merck & Co., Inc.
      • 11.10.1 Merck & Co., Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Merck & Co., Inc. Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Merck & Co., Inc. Hodgkin Lymphoma Treatment Products Offered
      • 11.10.5 Merck & Co., Inc. Recent Development
    • 11.11 Mirati Therapeutics Inc.
    • 11.12 Molecular Templates Inc.
    • 11.13 NantKwest, Inc.

    12 Future Forecast

    • 12.1 Hodgkin Lymphoma Treatment Market Forecast by Regions
      • 12.1.1 Global Hodgkin Lymphoma Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Hodgkin Lymphoma Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Hodgkin Lymphoma Treatment Market Forecast by Product
      • 12.2.1 Global Hodgkin Lymphoma Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Hodgkin Lymphoma Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Hodgkin Lymphoma Treatment Market Forecast by End User
    • 12.4 North America Hodgkin Lymphoma Treatment Forecast
    • 12.5 Europe Hodgkin Lymphoma Treatment Forecast
    • 12.6 Asia Pacific Hodgkin Lymphoma Treatment Forecast
    • 12.7 Central & South America Hodgkin Lymphoma Treatment Forecast
    • 12.8 Middle East and Africa Hodgkin Lymphoma Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Hodgkin Lymphoma Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Hodgkin Lymphoma Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hodgkin Lymphoma Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Hodgkin Lymphoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hodgkin Lymphoma Treatment in these regions.
      This research report categorizes the global Hodgkin Lymphoma Treatment market by top players/brands, region, type and end user. This report also studies the global Hodgkin Lymphoma Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Cell Medica Limited
      Cellular Biomedicine Group, Inc.
      Constellation Pharmaceuticals, Inc.
      Curis, Inc.
      Faron Pharmaceuticals Oy
      Fate Therapeutics, Inc.
      Gamida Cell Ltd.
      Gilead Sciences, Inc.
      Incyte Corporation
      Merck & Co., Inc.
      Mirati Therapeutics Inc.
      Molecular Templates Inc.
      NantKwest, Inc.

      Market size by Product
      Alocrest
      ANK Program
      Azacitidine
      BMS-986016
      BPX-501
      Others
      Market size by End User
      Hospital
      Clinic
      Research Center

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Hodgkin Lymphoma Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Hodgkin Lymphoma Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Hodgkin Lymphoma Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Hodgkin Lymphoma Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Hodgkin Lymphoma Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hodgkin Lymphoma Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now